StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

(2,5-Dihydroxyphenyl)essigsure

Homogentisic Acid

HCID 780
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
451-13-8
Standard-SMILES
O=C(O)Cc1cc(O)ccc1O
InChIKey
IGMNYECMUMZDDF-UHFFFAOYSA-N
Summenformel
C8H8O4
Durchschnittliche Molmasse
168,15 g/mol
Monoisotopische Masse
168,04225874

Überblick

Homogentisic acid is a dihydroxyphenylacetic acid having the two hydroxy substituents at the 2- and 5-positions. It has a role as a plant metabolite and a human metabolite. It is a member of hydroquinones and a dihydroxyphenylacetic acid. It is functionally related to a phenylacetic acid. It is a conjugate acid of a homogentisate.

Namen und Bezeichner

Bevorzugter Name
Homogentisic Acid
IUPAC
2-(2,5-dihydroxyphenyl)acetic acid
Lokaler Name
(2,5-Dihydroxyphenyl)essigsure
Englischer Name
Homogentisic acid
Summenformel
C8H8O4
Molmasse
168.15

Namen und Synonyme

Homogentisic acid451-13-82,5-Dihydroxyphenylacetic acid2-(2,5-dihydroxyphenyl)acetic acidAlcaptonHomogentisinic acidHomogentisate acidhomogentisate2,5-Dihydroxybenzeneacetic acid2,5-Dihydroxy-alpha-toluic acidBenzeneacetic acid, 2,5-dihydroxy-2,5-Dihydroxyphenylacetate
Weitere Namen anzeigen
Melanic acidhomogentisicaciHOMOGENTISIC ACID(RG)Homogentisic Acid >Homogentisic Acid, ≥ 97.0%
NP8UE6VF08NSC-88940DTXSID1060005CHEBI:44747CHEBI:16169Acid, HomogentisicRefChem:788461DTXCID6040375

Datenbank-Bezeichner

CAS
451-13-8、71694-00-3
PubChem CID
780
DTXSID
DTXSID1060005
ChEBI
CHEBI:44747
UNII
NP8UE6VF08
EC Number
207-192-7
Nikkaji
J5.750I

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
0,5
Polarare Oberfläche (TPSA)
77,8 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
2
Schwere Atome
12
Formalladung
0
Komplexität
168

Experimentelle und physikochemische Eigenschaften

Chemical ClassesOther Classes -> Organic Acids
Drugs · 2 Einträge

Pharmaceuticals -> Metabolite of Diclofenac

Pharmaceuticals -> Listed in ZINC15

LogP · 2 Einträge

0.86

0.86

Solubility850 mg/mL at 25 °C
Melting Point153 °C
Vapor Pressure0.00000082 [mmHg]
Physical Description · 2 Einträge

Beige crystalline solid; [Sigma-Aldrich MSDS]

Solid

Collision Cross Section · 3 Einträge

132.4 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

135.9 Ų [M+H-H2O]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

132.7 Ų [M-H]-

Physikochemische Eigenschaften

Schmelzpunkt
150 · 150-152 °C (lit.)
Siedepunkt
257.07 °C · 257.07°C (rough estimate)
Dichte
1.3037 · 1.3037 (rough estimate)
Brechungsindex
1.509 · 1.5090 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
Soluble in methanol.
pka
4.4 · 4.4(at 25℃)
Aggregatzustand
crystalline
Farbe
off-white to tan
Wasserlöslichkeit
very faint turbidity
Merck
14 · 14,4737
BRN
2692860 · 2692860
Major Application
food and beverages
InChI
1S/C8H8O4/c9-6-1-2-7(10)5(3-6)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)
InChIKey
IGMNYECMUMZDDF-UHFFFAOYSA-N
SMILES
OC(=O)Cc1cc(O)ccc1O
LogP
0.86 · 0.860
CAS Datenbank
451 · 451-13-8(CAS DataBase Reference)
EPA chemische Informationen
2 · Benzeneacetic acid, 2,5-dihydroxy- (451-13-8)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazards SummaryCauses changes in urine composition in 5-day intermittent intraperitoneal studies of rats; [RTECS] A skin and strong eye irritant; [Sigma-Aldrich MSDS]
Hazard Classes and CategoriesSkin Irrit. 2 (100%)

Toxikologische Informationen

Treatment · 1 Eintrag

Apart from treatment of the complications (such as pain relief using NSAIDs and joint replacement for the cartilage damage), vitamin C has been used to reduce the ochronosis and lowering of the homogentisic acid levels may be attempted with a low-protein diet. Recently the drug nitisinone has been found to suppress homogentisic acid production. Nitrisinone inhibits the enzyme, 4-hydroxyphenylpyruvate dioxygenase, responsible for converting tyrosine to homogentisic acid, thereby blocking the production and accumulation of homogentisic acid. Nitisinone treatment has been shown to cause a 95% reduction in plasma and urinary homogentisic acid.

Health Effects · 1 Eintrag

Homogentisic acid is only toxic under chronic exposure. One of the first symptoms of alkaptonuria is darkening of urine on standing (due to the oxidation of homogentisic acid). In most pediatric patients, darkening of urine is the only feature suggesting alkaptonuria. Most patients are usually asymptomatic until age 30. Scleral pigmentation usually starts around age 30. Skin pigmentation becomes obvious by the time patients reach age 40. One of the first sites to be affected is the ear cartilage. There may be discoloration of the forehead, cheeks, axilla, genitalia, palms, nails and soles. Ochronotic arthropathy starts around the 4th decade. Weight-bearing joints like the knees and the intervertebral joints in the spine, as well as the shoulder joints, are involved, with narrowing of joint spaces and disc calcifications. Arthritis is the only disabling effect of this condition and occurs in almost all patients as age advances. Ochronotic arthropathy can be so severe as to require total joint replacement. Pigment deposits can be seen in the larynx, tonsils, esophagus, dura mater, eardrums, trachea, and bronchi. Aortic or mitral valvulitis, calcification of coronary arteries and atherosclerotic plaques are seen after the age of 50 years.

Toxicity Summary · 1 Eintrag

Extremely high levels of homogentisic acid are found in patients with the inborn error of metabolism (IEM) called Alkaptonuria. Homogentisic acid spontaneously undergoes oxidation into benzoquinone acetic acid (BQA), which polymerizes forming plasma soluble melanins (PSM). The PSM darkens many tissues (ochronosis - as the tissue looks like ochre), and produces widespread degenerative changes in cartilage and other connective tissues, joints, blood vessels, heart valves and the kidneys. Ochronotic tissue is stiff and unusually brittle. The accumulation of PSM in chondrocytes (the cells that form cartilage) leads to profound alterations in the levels of proteins involved in cell defense, protein folding, and cell organization. An increased post-translational oxidation of proteins, which also involved high molecular weight protein aggregates, has been found to be particularly evident in chondrocytes from patients with alkaptonuria.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Sicherheitsdaten

wgk
3
tsca
TSCA listed
hs_code
2918290000
RTECS-Nr.
AH0589000
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
Speicherklasse
13 - Non Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

Tissue LocationsCartilage
Cellular LocationsCytoplasm
Metabolite PathwaysAlkaptonuria

Verwendung und Herstellung

UsesFound in plants and in the urine of alkaptonurics; A product of tyrosine and phenylalanine metabolism; [Merck Index]
General Manufacturing InformationBenzeneacetic acid, 2,5-dihydroxy-: ACTIVE
Anwendungen · 1 Eintrag

VerwendenHomogentisic acid may be used as an analytical reference standard for the quantification of the analyte in the following:Urine matrices using reversed-phase liquid chromatography tandem mass spectrometry (LC-MS/MS).Strawberry tree honey samples using reversed phase-high performance liquid chromatography (RP-HPLC) and ion chromatography (IC).It may also be used as an internal standard for the determination of ascorbic acid (AA) and uric acid (UA) in human plasma samples using high-pressure liquid chromatography–electrochemical detection (HPLC–ECD).

Vor- und nachgelagerte Produkte

Nachgelagerte Produkte

m-Hydroxyphenylessigsurefumarylacetoacetate

Zugehörige Reaktionen

9
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 29498
HRID 29498als Edukt
Reaktionsgleichung von HRID 724514
HRID 724514als Edukt
Reaktionsgleichung von HRID 915515
HRID 915515als Edukt
Reaktionsgleichung von HRID 985639
HRID 985639als Edukt
Reaktionsgleichung von HRID 1263387
HRID 1263387als Edukt
Reaktionsgleichung von HRID 1393875
HRID 1393875als Edukt
Reaktionsgleichung von HRID 1551388
HRID 1551388als Edukt
Reaktionsgleichung von HRID 1811658
HRID 1811658als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung